Capreomycin sulfate indications and usage: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Capreomycin sulfate}} {{CMG}} ; {{AE}}{{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CAPASTAT SULFATE (CAPREOMYCIN) INJE..." |
Gerald Chi (talk | contribs) mNo edit summary |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Capreomycin sulfate}} | {{Capreomycin sulfate}} | ||
{{CMG}} ; {{AE}}{{chetan}} | {{CMG}} ; {{AE}} {{chetan}} | ||
==Indications and Usage== | |||
Capastat sulfate, which is to be used concomitantly with other appropriate antituberculosis agents, is indicated in pulmonary infections caused by capreomycin-susceptible strains of M. tuberculosis when the primary agents ([[isoniazid]], [[rifampin]], [[ethambutol]], [[aminosalicylic acid]], and [[streptomycin]]) have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli. | |||
Susceptibility studies should be performed to determine the presence of a capreomycin-susceptible strain of M. tuberculosis.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CAPASTAT SULFATE (CAPREOMYCIN) INJECTION, POWDER, FOR SOLUTION [AKORN] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=808e4421-2b9c-41e1-a82c-39256b112ae8 | publisher = | date = | accessdate }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CAPASTAT SULFATE (CAPREOMYCIN) INJECTION, POWDER, FOR SOLUTION [AKORN] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=808e4421-2b9c-41e1-a82c-39256b112ae8 | publisher = | date = | accessdate | |||
==References== | ==References== | ||
Latest revision as of 23:45, 25 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Indications and Usage
Capastat sulfate, which is to be used concomitantly with other appropriate antituberculosis agents, is indicated in pulmonary infections caused by capreomycin-susceptible strains of M. tuberculosis when the primary agents (isoniazid, rifampin, ethambutol, aminosalicylic acid, and streptomycin) have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli.
Susceptibility studies should be performed to determine the presence of a capreomycin-susceptible strain of M. tuberculosis.[1]
References
- ↑ "CAPASTAT SULFATE (CAPREOMYCIN) INJECTION, POWDER, FOR SOLUTION [AKORN]". Text " accessdate " ignored (help)
Adapted from the FDA Package Insert.